Webster W Scott, Small Eric J, Rini Brian I, Kwon Eugene D
Department of Urology, Mayo Clinic and Mayo Medical School, 200 1st St SW, Rochester, MN 55905, USA.
J Clin Oncol. 2005 Nov 10;23(32):8262-9. doi: 10.1200/JCO.2005.03.4595.
A number of recently developed and promising approaches to antitumoral immunotherapy are being investigated as potential treatments for advanced prostate cancer. These approaches largely revolve around strategies to increase antigen-specific T-cell activation against prostate tumors as well as precise manipulations of critical co-regulatory receptors that help to maintain and prolong the activity of antigen-presenting cells and T cells that are capable of mediating tumor regression. Herein, we describe the experience with the most recent and promising approaches pertaining to prostate cancer immunotherapy. Additionally, we discuss the mechanistic basis for these approaches as well as current limitations that must still be addressed in order to propel immunotherapy into the forefront of prostate cancer treatment.
一些最近开发且前景看好的抗肿瘤免疫疗法正作为晚期前列腺癌的潜在治疗方法进行研究。这些方法主要围绕增强针对前列腺肿瘤的抗原特异性T细胞活化的策略，以及对关键共调节受体的精确操控，这些受体有助于维持和延长能够介导肿瘤消退的抗原呈递细胞和T细胞的活性。在此，我们描述了前列腺癌免疫疗法中最新且最具前景的方法的经验。此外，我们讨论了这些方法的机制基础以及为将免疫疗法推向前列腺癌治疗前沿仍需解决的当前局限性。
